All Outputs (3)

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling : implicating TIGAR in somatic resistance to endocrine therapy (2018)
Journal Article
Fiorillo, M., Sanchez-Alvarez, R., Sotgia, F., & Lisanti, M. (2018). The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling : implicating TIGAR in somatic resistance to endocrine therapy. Aging, 10(12), 4000-4023. https://doi.org/10.18632/aging.101690

Naturally-occurring somatic mutations in the estrogen receptor gene (ESR1) have been previously implicated in the clinical development of resistance to hormonal therapies, such as Tamoxifen. For example, the somatic mutation Y537S has been specifical... Read More about The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling : implicating TIGAR in somatic resistance to endocrine therapy.

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs) : MITO-ONC-RX (2018)
Journal Article
Sotgia, F., Ozsvari, B., Fiorillo, M., De Francesco, E., Bonuccelli, G., & Lisanti, M. (2018). A mitochondrial based oncology platform for targeting cancer stem cells (CSCs) : MITO-ONC-RX. Cell Cycle, 17(17), 2091-2100. https://doi.org/10.1080/15384101.2018.1515551

Here, we wish to propose a new systematic approach to cancer therapy, based on the targeting of mitochondrial metabolism, especially in cancer stem cells (CSCs). In the future, we envision that anti-mitochondrial therapy would ultimately be practiced... Read More about A mitochondrial based oncology platform for targeting cancer stem cells (CSCs) : MITO-ONC-RX.

Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism (2018)
Journal Article
Fiorillo, M., Peiris-Pagès, M., Sanchez-Alvarez, R., Bartella, L., Di Donna, L., Dolce, V., …Lisanti, M. (2018). Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism. BBA - Bioenergetics, 1859(9), 984-996. https://doi.org/10.1016/j.bbabio.2018.03.018

Here, we show that a 2:1 mixture of Brutieridin and Melitidin, termed “BMF”, has a statin-like properties, which
blocks the action of the rate-limiting enzyme for mevalonate biosynthesis, namely HMGR (3-hydroxy-3-methylglutaryl-
CoA-reductase). Mor... Read More about Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism.